2-(Trimethylsilyl)-1,3-Thiazole

2-(Trimethylsilyl)-1,3-thiazole (CAS 79265-30-8), an organosilicon heterocycle in which a trimethylsilyl group occupies the 2-position of the thiazole ring, is supplied as a colourless to pale yellow liquid with a characteristic thiazoline-like odour. The molecular formula C₆H₁₁NSi and a molecular weight of 141.24 g mol⁻¹ correspond to a compound that serves primarily as a protected formyl anion equivalent in heterocyclic chemistry. The silyl moiety simultaneously blocks the inherently acidic C2 position while rendering the C5 hydrogen sufficiently acidic for directed metalation. Commercial production typically achieves a purity of ≥97.0% (GC) with the balance consisting largely of 1,3-thiazole and hexamethyldisiloxane arising from residual moisture contact during handling. The compound is listed on the EINECS inventory under number 279-486-7 and is pre-registered under REACH for import volumes between 1 and 10 tonnes per annum in the EU. Industrial shipments employ 25 mL to 200 L fluorinated HDPE containers purged with argon to <5 ppm O₂ headspace oxygen concentration as measured by a Teledyne 311 trace oxygen analyser.

Physicochemical Specifications and Typical Lot Data

Property	Method	Specification	Typical Value
Assay (GC)	In-house GC-FID, 30 m DB-5 column	≥97.0%	98.5%
Water content	ASTM E203 (Karl Fischer coulometric)	≤0.10%	0.03%
Density at 20 °C	ASTM D4052	0.980–0.992 g/mL	0.985 g/mL
Refractive index nD20	ASTM D1218	1.498–1.502	1.500
Boiling range	ASTM D86 (reduced pressure)	85–88 °C/20 mmHg	86 °C/20 mmHg
Flash point (closed cup)	ASTM D93	53–57 °C	55 °C
Appearance	Visual	Clear, colourless to pale yellow liquid	Passes
Heavy metals (as Pb)	ICP-MS (USP <231>)	≤10 ppm	<2 ppm

The above specifications refer to material stabilised with 50–100 ppm BHT to suppress radical-induced discolouration during extended storage. Batches tested after 12 months at 2–8 °C under argon show assay retention within 0.3% of the original value. The GC-FID method employs a split ratio of 100:1 and injector temperature of 250 °C; the characteristic retention time for the silylated thiazole is 4.2 min, well resolved from early-eluting hexamethyldisiloxane (1.8 min) and free thiazole (2.6 min). ¹H NMR (CDCl₃, 400 MHz) confirms structure through the diagnostic nine-proton singlet at δ 0.38 (Si(CH₃)₃), the C5 proton doublet at δ 7.45 (J = 3.2 Hz), and the C4 proton doublet at δ 8.85 (J = 3.2 Hz).

How Does the Silyl Substituent Enable Use as a Masked Formyl Equivalent?

The trimethylsilyl group at C2 serves a dual function: it sterically and electronically passivates what would otherwise be the most acidic C–H bond in the thiazole nucleus (pKa ~ 29 in THF for 2-H in unsubstituted thiazole) and it can be unmasked to a formyl group under mild conditions. Deprotonation at C5 using lithium diisopropylamide (LDA, 1.05 equiv) in anhydrous THF at –78 °C generates the corresponding 5-lithio-2-(trimethylsilyl)thiazole within 45–60 min. Quenching with an electrophile—aldehydes, alkyl halides, isocyanates—then yields a 5‑substituted thiazole still bearing the silyl protecting group. Subsequent exposure to 1.0 M tetra-n-butylammonium fluoride (TBAF) in THF at 0 °C to room temperature over 2 h delivers the 5-substituted thiazole-2-carbaldehyde. This two-step sequence avoids the direct handling of thiazole-2-carbaldehyde, which is prone to rapid air oxidation and self-condensation; the silylated precursor remains bench-stable for months. The yield of isolated aldehyde after flash chromatography (silica gel, hexane/EtOAc 8:2) routinely exceeds 75% for a range of aromatic aldehydes as electrophiles. With less reactive alkyl halides, a copper(I) iodide additive (0.2 equiv) improves coupling efficiency, raising isolated yields from the 50–60% range to >80% in documented procedures. In medicinal chemistry campaigns, this methodology has been applied to the synthesis of 5-arylthiazole-2-carboxamides where the aldehyde intermediate is further oxidised to the carboxylic acid with NaClO₂ under buffered conditions or directly converted to a nitrile via aldoxime dehydration. The silylated intermediate is compatible with parallel synthesis equipment, including Mettler-Toledo EasyMax reactors, enabling exotherm control during the lithiation quench with a jacket set-point of –75 °C and a stirring rate of 400 rpm. The compound also functions as a protected thiazole in strategies requiring temporary blocking of the C2 position during subsequent functionalisation at C4 or C5 that would otherwise be compromised by C2‑directed metalation. For example, subsequent bromination of the 5‑substituted silylthiazole with N‑bromosuccinimide (NBS) in DMF at 0 °C yields the 4‑bromo derivative with complete regioselectivity; the silyl group remains intact. When palladium-catalysed cross-coupling sequences are preferred over deprotonative metalation, 2-(trimethylsilyl)-1,3-thiazole is converted into the corresponding 5‑stannane or 5‑boronic ester. Treatment with 1.05 equiv of n-BuLi in THF at –78 °C followed by quenching with tri-n-butyltin chloride yields the 5‑stannane, which participates in Stille couplings with aryl bromides using Pd(PPh₃)₄ (2 mol%) in refluxing toluene. The silyl group is removed post-coupling with TBAF as before. Published data for this specific two-electron oxidative addition–transmetalation manifold with electron-deficient aryl bromides report isolated yields of 72–88% after desilylation. The protocol circumvents the need for pre-formed thiazole-5-boronic acid, a substrate known to undergo rapid protodeboronation in protic media.

When the 5‑Lithiation Pathway Competes with Premature Desilylation

The operational window for efficient C5 functionalisation without concomitant loss of the silyl group is narrow and parameter-dependent. At lithiation temperatures above –65 °C, lithium-halogen exchange or nucleophilic attack at the silicon centre becomes competitive, leading to desilylated thiazole and LiTMS adducts. The presence of free chloride ions, even at trace levels from LDA preparation, accelerates desilylation, reducing the effective concentration of the desired 5‑lithio intermediate. Rigorous use of freshly titrated LDA (1.00–1.10 M in THF/heptane/ethylbenzene), prepared at 0 °C from diisopropylamine and n-BuLi, and maintained below –70 °C during addition to the silylthiazole, is critical. Under these conditions, the competitive desilylation rate constant is measured at k_rel ~ 0.05 relative to deprotonation at C5, as determined by in situ ReactIR monitoring of the Si–C stretching band at 840 cm⁻¹. The use of TMEDA as a co-solvent (1.2 equiv) can enhance the rate of C5 lithiation but simultaneously broadens the desilylation pathway; its addition is justified only when electrophiles of exceptionally low reactivity are employed. Additionally, residual moisture in either THF or the electrophile introduces protodesilylation, generating thiazole and hexamethyldisiloxane. The THF used must be freshly distilled from sodium/benzophenone ketyl under argon, and the electrophile must be rigorously dried—aldehydes over 3 Å molecular sieves for ≥72 h, alkyl halides passed through a plug of basic alumina (activity I) immediately before use. Failure to control water content to <30 ppm (Karl Fischer) results in isolated yields of the desired aldehyde dropping below 40%, with thiazole-2-carbaldehyde becoming the dominant product after TBAF treatment, indicating extensive desilylation prior to electrophilic capture.

Contrasting Reactivity with 2‑(Trimethylsilyl)oxazole and 2‑(Trimethylsilyl)thiophene

Substitution of the ring heteroatom in position 3 from sulfur (thiazole) to oxygen (oxazole) or replacement of the sulfur with a carbon atom (thiophene) dramatically alters the kinetic acidity of the remaining C–H bonds and the stability of the silyl moiety toward nucleophiles. 2‑(Trimethylsilyl)oxazole (CAS 13750-83-5) undergoes lithiation at C5 more readily, with LDA at –78 °C producing the 5‑lithio species in <30 min; however, the silyl group is significantly more labile, with appreciable desilylation observed even at –90 °C in the presence of trace fluoride released from the TMS group itself. The oxazole analogue therefore demands even stricter exclusion of TBAF-like contaminants and delivers lower yields of the formyl equivalent product (55–70% upon desilylation) in direct comparison studies. 2‑(Trimethylsilyl)thiophene (CAS 18245-28-8) exhibits the opposite behaviour. The thiophene ring possesses lower electron-withdrawing character, raising the C5 pKa to the point that LDA-promoted deprotonation is sluggish, requiring temperatures of –40 °C to –20 °C and longer reaction times (3–4 h). At these temperatures, the silyl group is largely stable, but regioselectivity can be compromised by competitive C3 lithiation. The thiophene silyl compound is therefore more suited to halogen–lithium exchange strategies or to reactions where the TMS group serves solely as a protecting group rather than a formyl precursor.

Property	2‑(Trimethylsilyl)-1,3-thiazole	2‑(Trimethylsilyl)oxazole	2‑(Trimethylsilyl)thiophene
Ring heteroatom	Sulfur at position 3	Oxygen at position 3	None (all carbon)
C5 lithiation base	LDA, –78 °C	LDA, –78 °C	LDA, –40 to –20 °C
Typical lithiation time	45–60 min	20–30 min	180–240 min
TMS desilylation half-life in LDA/THF at –78 °C	>4 h	<1.5 h	>8 h
Masked formyl yield (PhCHO quench)	75–85%	55–70%	40–55% (over two steps)
Suzuki coupling feasibility via 5‑boronate	Yes, stable boronate	Boronate prone to protodeboronation	Yes, stable boronate

For applications demanding high electrophile scope, broad functional group tolerance, and a balance between lithiation rate and silyl stability, 2‑(trimethylsilyl)-1,3‑thiazole occupies an optimal position among the common silylated azoles and thiophene. The thiazole ring’s electron-withdrawing power, intermediate between oxazole and thiophene, produces a C5 pKa that allows for commercial-scale lithiation in jacketed glass reactors without requiring cryogenic liquid nitrogen cooling below –100 °C or the addition of expensive co-solvents.

Managing Hydrolytic Instability and Headspace Moisture During Storage

The Si–C bond in 2‑(trimethylsilyl)-1,3‑thiazole is susceptible to hydrolytic cleavage, the rate being pH- and moisture-dependent. At 25 °C and ambient relative humidity (50% RH), a sample stored under air in a capped but non-septum-sealed vial shows 1.5% desilylation per day, as monitored by GC. Storage under argon or nitrogen with a positive pressure of 50 mbar reduces this to <0.05% per day. The product is therefore packaged exclusively under argon, with containers fitted with PTFE-lined septa and tamper-evident aluminium crimp seals. Long-term storage is recommended at 2–8 °C; below 0 °C the liquid solidifies (melting point ≈ –30 °C), and repeated freeze-thaw cycles introduce micro‑condensation on vial headspace walls, accelerating desilylation. Incompatible materials include protic solvents (water, alcohols, carboxylic acids), amine bases hotter than diisopropylamine that can catalyse desilylation, and fluoride ion sources (including glass etched with HF or previously used for fluoride salts). Stainless steel transfer lines are acceptable provided they are passivated with 5% HNO₃ and rinsed with anhydrous THF before use. Polytetrafluoroethylene and borosilicate glass are the preferred wetted materials. The compound exhibits no autopolymerisation tendency but forms Hazen-coloured oligomers when heated above 100 °C for prolonged periods in the presence of adventitious acid. Compliance documentation includes a Certificate of Analysis specifying lot-specific GC assay, water content, and density. Safety data sheets reference the flash point of 55 °C (ASTM D93) and classify the substance as a combustible liquid with specific target organ toxicity (STOT SE 3, respiratory irritation) per CLP Regulation (EC) No 1272/2008. On global toxic substance control inventories, the substance is listed on the US TSCA inventory, EINECS, and the Japanese ENCS (MITI number 5-9851). Customers requiring larger quantities (≥25 kg) are advised to confirm local registration status for their intended use sector, particularly if pharmaceutical intermediate applications require EU GMP Part II documentation or a drug master file (DMF) submission. The product is not currently supported under a US FDA Type II DMF; however, the supplied analytical package and residual solvent statement (Class 3 solvents only) meet the documentation requirements for early-phase GLP toxicology batch evaluation.